What happened with KZIA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Kazia Therapeutics is developing paxalisib, designed to reach the brain to treat brain cancer, and EVT801, another cancer drug candidate. Neither has regulatory approval. The company relies on outside manufacturers and research providers to supply drugs and carry out preclinical studies and clinical trials.
Kazia licenses paxalisib to partners that take responsibility for development, registration and commercialization: Simcere Pharmaceutical Group in Greater China and Sovargen outside that territory. These agreements provide for upfront payments, payments when development or regulatory milestones are reached, and royalties if commercial sales begin. Licensing income is irregular, and Kazia has not generated significant revenue or commercial sales of approved medicines.
Operations are funded mainly by issuing shares, alongside Australian government research grants and collaboration-partner payments. Continued development depends on raising more money; future drug revenue depends on successful trials, regulatory approval and partners bringing treatments to market. In its 2025 filing, Kazia also reported that U.S. securities rules tied to its public float restricted how much it could raise through primary public offerings.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Kazia Therapeutics Limited hinges on clinical and regulatory progress for Paxalisib and EVT801; Simcere and Sovargen, absent from this list, hold important Paxalisib development and commercialization rights.
Kazia controls EVT801’s development worldwide, but owes Evotec SE contingent milestone payments and royalties on net sales under its exclusive license. Evotec, which also sells drug-research and development services, has no right to direct EVT801’s development; watch for payments tied to this candidate’s progress and sales.
MediciNova and Kazia are developing glioblastoma treatments that compete to improve on the same limited options for patients. MediciNova has no marketing or sales capabilities and expects partners to commercialize its products, so watch its glioblastoma development progress rather than current product sales.
Celcuity Inc. names Kazia as a therapeutic competitor: its gedatolisib and Kazia’s Paxalisib both block PI3K/mTOR cancer-growth signals, although gedatolisib is being tested in breast and prostate cancer. Watch gedatolisib’s trial results as a comparison for this treatment approach, not as direct evidence for Paxalisib in brain cancer.
Zai Lab already commercializes OPTUNE for glioblastoma in Greater China—the mainland, Hong Kong, Macau and Taiwan—where Kazia has given Simcere responsibility for developing and commercializing Paxalisib. Watch OPTUNE’s commercial progress as an existing treatment competing for the patient group Paxalisib would seek to serve.
Relay Therapeutics’ clinical results for zovegalisib, which selectively blocks mutant PI3Kα, can help investors assess the promise and limitations of Kazia’s broader PI3K inhibitor Paxalisib. Watch zovegalisib’s efficacy and safety results as evidence about this treatment approach, rather than proof that Paxalisib will perform the same way.
Evotec SE earningsEVO
Evotec SE’s report shows conditions in the drug-development services business, while Kazia’s milestone and royalty payments for EVT801 depend on the candidate’s progress and sales.
Read Evotec’s services activity as a signal about demand for its own research and development work, not as evidence of EVT801 progress or a payment due from Kazia. Stronger activity suggests a firmer services market; weaker activity suggests pressure there. Only EVT801 progress or sales meeting the agreement’s conditions would trigger Kazia’s related payments.
Zai Lab Limited earningsZLAB
Zai Lab’s report will show OPTUNE’s commercial progress in Greater China, where it already treats glioblastoma patients and could compete with Paxalisib for patients.
Read OPTUNE’s commercial progress as evidence about an existing treatment in the region, not as clinical evidence for Paxalisib. Strong progress would point to a more established competitor for the same patient group if Paxalisib reaches the market there; weak progress would show less commercial traction for OPTUNE, not that patients would switch to Paxalisib.
Celcuity Inc. earningsCELC
Celcuity’s report may update gedatolisib trials, offering a comparison for the PI3K/mTOR approach shared with Paxalisib, though the drugs are being tested in different cancers.
Look at gedatolisib’s trial efficacy and safety as a comparison for the PI3K/mTOR approach, not as a substitute for evidence on Paxalisib in brain cancer. Clear benefit with acceptable safety would strengthen the clinical case for the approach and sharpen competition for development resources; limited benefit or safety concerns would weaken that signal. Kazia’s own trials must establish Paxalisib’s performance in brain cancer.
Medicinova, Inc. earningsMNOV
MediciNova’s report can show its glioblastoma program’s progress, providing a competitor comparison for Kazia’s Paxalisib in the same patient group.
Look for clinical progress in MediciNova’s glioblastoma program and for reported efficacy or safety concerns. Smooth progress would add a potential candidate competing with Paxalisib for the same patient group; setbacks would weaken that competitive signal. MediciNova has no marketing or sales capabilities and expects partners to commercialize its products, so this is a development comparison, not a read on current product sales.
